{ "run": { "id": "cmnr15ijr06xsp658mbfqgxaq", "region": "US", "assetId": "cmnr15ij906xop658vk6u1uiq", "ticker": "VTRS", "snapshotId": "cmnr15iji06xqp658yv05a134", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:07.525Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15iji06xqp658yv05a134", "assetId": "cmnr15ij906xop658vk6u1uiq", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 13.5, "price": 13.57, "dayLow": 13.4, "volume": 6629401, "dayHigh": 13.66, "currency": "USD", "prevClose": 13.16, "week52Low": 6.85, "week52High": 16.47 }, "fundamentals": { "pe": -4.15, "beta": 0.771080745102619, "epsTTM": -3, "fcfTTM": -55700000, "growth": { "epsYoy": -4.660377358490566, "revenueYoy": -0.02981145644637127 }, "sector": "Pharmaceutical Preparations", "margins": { "net": -0.2457989216707809, "gross": 0.3505968573206806, "operating": -0.1862320715529479 }, "website": "http://viatris.com", "industry": "Pharmaceuticals", "pegRatio": -0.00890485829959514, "ebitdaTTM": -174500000, "forwardPe": 4.98, "marketCap": 10384706269, "totalCash": 1322400000, "totalDebt": 14410500000, "debtEquity": 0.979553132625941, "quickRatio": 0.5554741130203121, "revenueTTM": 14299900000, "companyName": "Viatris Inc", "priceToBook": 0.991539496567264, "currentRatio": 1.379868345009374, "dividendYield": 0.0395630717811086, "returnOnAssets": -0.09450408812387244, "returnOnEquity": -0.238925179963701, "analystOpinions": null, "businessSummary": "Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.", "enterpriseValue": 27674934995.85, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 32000, "sharesOutstanding": 1151392922, "enterpriseToEbitda": -158.595616022063, "analystTargetMedian": null, "enterpriseToRevenue": 1.935323673301911, "operatingCashflowTTM": 2315900000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:07.519Z" }, "results": [ { "id": "cmnr15ijv06xup6586x1ebzxz", "runId": "cmnr15ijr06xsp658mbfqgxaq", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-sonnet-4-20250514\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"VTRS\",\"currency\":\"USD\",\"current_price\":13.57,\"target_price_6m\":14.80,\"target_price_12m\":15.60,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward PE ~5x signals deep value on adjusted earnings basis\",\"Operating cash flow of $2.3B supports deleveraging and 4% dividend\",\"Negative GAAP earnings driven by non-cash impairments, not operational weakness\",\"Revenue declining modestly at ~3% YoY poses medium-term headwind\",\"Heavy $14.4B debt load remains key risk despite active paydown\"],\"key_drivers\":[{\"driver\":\"Debt deleveraging trajectory from $14.4B total debt\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Adjusted earnings power vs depressed GAAP earnings\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Generic drug pricing pressure and portfolio erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Strong operating cash flow generation (~$2.3B TTM)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Dividend sustainability at ~4% yield\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Revenue decline trend (-3% YoY)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"New product launches and biosimilar pipeline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Interest expense burden from high leverage\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.77) provides defensive characteristics\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Accelerated generic competition eroding base business faster than expected\",\"Inability to refinance $14.4B debt at favorable rates in rising rate environment\",\"Goodwill impairment risk given P/B near 1x and prior large writedowns\",\"Pipeline execution failure limiting new revenue offsets\",\"Dividend cut risk if FCF remains constrained by debt service\"],\"assumptions\":{\"revenue_cagr_3y\":0.01,\"ebit_margin_target\":0.24,\"wacc\":0.09,\"terminal_multiple\":6.5},\"scenarios\":{\"bear\":{\"target_price\":10.50,\"prob\":0.20,\"notes\":\"Revenue erosion accelerates, debt refinancing concerns pressure multiple below 4x adjusted earnings.\"},\"base\":{\"target_price\":15.60,\"prob\":0.55,\"notes\":\"Stable revenue, continued deleveraging, market re-rates to ~6x adjusted forward earnings.\"},\"bull\":{\"target_price\":19.00,\"prob\":0.25,\"notes\":\"Biosimilar/new product launches drive revenue inflection, faster deleveraging enables multiple expansion to 7x+.\"}},\"method_notes\":\"Adjusted earnings-power approach: normalized EBIT margin ~24% on ~$14.5B revenue yields ~$3.5B EBIT; after tax and interest, adjusted EPS ~$2.55-2.75. Applied 5.5-6x forward P/E for base case. OCF yield (~22%) cross-checked as supportive. GAAP losses reflect non-cash intangible amortization/impairments from 2020 merger, not operational distress. Confidence moderate (0.62) due to debt overhang uncertainty and revenue trajectory risk. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "claude-sonnet-4-20250514", "risks": [ "Accelerated generic competition eroding base business faster than expected", "Inability to refinance $14.4B debt at favorable rates in rising rate environment", "Goodwill impairment risk given P/B near 1x and prior large writedowns", "Pipeline execution failure limiting new revenue offsets", "Dividend cut risk if FCF remains constrained by debt service" ], "ticker": "VTRS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Stable revenue, continued deleveraging, market re-rates to ~6x adjusted forward earnings.", "target_price": 15.6 }, "bear": { "prob": 0.2, "notes": "Revenue erosion accelerates, debt refinancing concerns pressure multiple below 4x adjusted earnings.", "target_price": 10.5 }, "bull": { "prob": 0.25, "notes": "Biosimilar/new product launches drive revenue inflection, faster deleveraging enables multiple expansion to 7x+.", "target_price": 19 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.01, "terminal_multiple": 6.5, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Debt deleveraging trajectory from $14.4B total debt", "impact": "HIGH", "direction": "POS" }, { "driver": "Adjusted earnings power vs depressed GAAP earnings", "impact": "HIGH", "direction": "POS" }, { "driver": "Generic drug pricing pressure and portfolio erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Strong operating cash flow generation (~$2.3B TTM)", "impact": "HIGH", "direction": "POS" }, { "driver": "Dividend sustainability at ~4% yield", "impact": "MED", "direction": "POS" }, { "driver": "Revenue decline trend (-3% YoY)", "impact": "MED", "direction": "NEG" }, { "driver": "New product launches and biosimilar pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Interest expense burden from high leverage", "impact": "MED", "direction": "NEG" }, { "driver": "Low beta (0.77) provides defensive characteristics", "impact": "LOW", "direction": "POS" } ], "method_notes": "Adjusted earnings-power approach: normalized EBIT margin ~24% on ~$14.5B revenue yields ~$3.5B EBIT; after tax and interest, adjusted EPS ~$2.55-2.75. Applied 5.5-6x forward P/E for base case. OCF yield (~22%) cross-checked as supportive. GAAP losses reflect non-cash intangible amortization/impairments from 2020 merger, not operational distress. Confidence moderate (0.62) due to debt overhang uncertainty and revenue trajectory risk. Not investment advice.", "current_price": 13.57, "recommendation": "BUY", "thesis_bullets": [ "Forward PE ~5x signals deep value on adjusted earnings basis", "Operating cash flow of $2.3B supports deleveraging and 4% dividend", "Negative GAAP earnings driven by non-cash impairments, not operational weakness", "Revenue declining modestly at ~3% YoY poses medium-term headwind", "Heavy $14.4B debt load remains key risk despite active paydown" ], "target_price_6m": 14.8, "target_price_12m": 15.6 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 39315, "createdAt": "2026-04-09T05:22:07.525Z", "usage": { "inputTokens": 3569, "outputTokens": 1760, "costUsd": 0.061845 } }, { "id": "cmnr15ijv06xxp658euji2nyq", "runId": "cmnr15ijr06xsp658mbfqgxaq", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"VTRS\",\n \"currency\": \"USD\",\n \"current_price\": 13.57,\n \"target_price_6m\": 13.8,\n \"target_price_12m\": 14.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"Post-merger integration offers cost synergy potential.\", \"High debt load constrains financial flexibility.\", \"Revenue decline challenges top-line growth.\", \"Positive operating cash flow supports liquidity.\", \"Low valuation multiples provide safety margin.\"],\n \"key_drivers\": [\n {\"driver\": \"Cost synergy execution\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Debt reduction efforts\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"New product launches\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Generic competition pressure\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory approval delays\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Currency exchange volatility\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n {\"driver\": \"Macroeconomic healthcare spending\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\"High leverage and default risk\", \"Intense generic market competition\", \"Merger integration failures\", \"Regulatory pricing pressures\", \"R&D pipeline setbacks\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.05,\n \"wacc\": 0.085,\n \"terminal_multiple\": 5.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 12.0, \"prob\": 0.3, \"notes\": \"Continued decline and high debt pressure.\"},\n \"base\": {\"target_price\": 14.0, \"prob\": 0.5, \"notes\": \"Stable performance with minor improvements.\"},\n \"bull\": {\"target_price\": 16.0, \"prob\": 0.2, \"notes\": \"Successful turnaround and growth.\"}\n },\n \"method_notes\": \"DCF with terminal P/E multiple. HOLD due to low expected upside and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "High leverage and default risk", "Intense generic market competition", "Merger integration failures", "Regulatory pricing pressures", "R&D pipeline setbacks" ], "ticker": "VTRS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Stable performance with minor improvements.", "target_price": 14 }, "bear": { "prob": 0.3, "notes": "Continued decline and high debt pressure.", "target_price": 12 }, "bull": { "prob": 0.2, "notes": "Successful turnaround and growth.", "target_price": 16 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.02, "terminal_multiple": 5, "ebit_margin_target": 0.05 }, "key_drivers": [ { "driver": "Cost synergy execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction efforts", "impact": "HIGH", "direction": "POS" }, { "driver": "New product launches", "impact": "MED", "direction": "POS" }, { "driver": "Generic competition pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory approval delays", "impact": "MED", "direction": "NEG" }, { "driver": "Currency exchange volatility", "impact": "LOW", "direction": "NEG" }, { "driver": "Macroeconomic healthcare spending", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF with terminal P/E multiple. HOLD due to low expected upside and mixed evidence. Not investment advice.", "current_price": 13.57, "recommendation": "HOLD", "thesis_bullets": [ "Post-merger integration offers cost synergy potential.", "High debt load constrains financial flexibility.", "Revenue decline challenges top-line growth.", "Positive operating cash flow supports liquidity.", "Low valuation multiples provide safety margin." ], "target_price_6m": 13.8, "target_price_12m": 14 }, "errorsJson": { "attempts": [ { "error": "provider_error: terminated", "attempt": 0, "rawOutputTruncated": null }, { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 1, "rawOutputTruncated": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"VTRS\",\n \"currency\": \"USD\",\n \"current_price\": 13.57,\n \"target_price_6m\": 14.0,\n \"target_price_12m\": 15.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"Post-merger integration offers cost synergy potential.\", \"High debt load constrains financial flexibility.\", \"Revenue decline challenges top-line growth.\", \"Positive operating cash flow supports liquidity.\", \"Low valuation multiples provide safety margin.\"],\n \"key_drivers\": [\n {\"driver\": \"Cost synergy execution\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Debt reduction efforts\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"New product launches\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Generic competition pressure\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory approval delays\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Currency exchange volatility\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n {\"driver\": \"Macroeconomic healthcare spending\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\"High leverage and default risk\", \"Intense generic ma…" } ], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 336, "createdAt": "2026-04-09T05:22:07.525Z", "usage": { "inputTokens": 2711, "outputTokens": 3148, "costUsd": 0.002081 } }, { "id": "cmnr15ijv06xvp658qezcqhv9", "runId": "cmnr15ijr06xsp658mbfqgxaq", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_VTRS_Base\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"VTRS\",\n \"currency\": \"USD\",\n \"current_price\": 13.57,\n \"target_price_6m\": 14.20,\n \"target_price_12m\": 15.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Extremely low forward P/E of 4.98x prices in excessive generic market pessimism.\",\n \"Strong operating cash flow of $2.3B supports aggressive debt paydown and 4% dividend.\",\n \"Divestitures of non-core assets streamline operations and accelerate deleveraging targets.\",\n \"New product pipeline in complex injectables offers modest revenue stabilization.\",\n \"High debt load and generic pricing erosion remain significant overhangs on multiple expansion.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Debt reduction progress\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic drug pricing pressure\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Complex injectable approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Non-core asset divestitures\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Dividend sustainability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Continued base business erosion from generic price deflation.\",\n \"Failure to execute on planned divestitures at favorable valuations.\",\n \"Regulatory delays for complex generic and biosimilar pipeline assets.\",\n \"High leverage ratio limits strategic flexibility and M&A opportunities.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": -0.01,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 5.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 11.00,\n \"prob\": 0.25,\n \"notes\": \"Generic pricing worsens, deleveraging stalls, and multiple compresses to 4x forward earnings.\"\n },\n \"base\": {\n \"target_price\": 15.00,\n \"prob\": 0.55,\n \"notes\": \"Steady OCF allows debt paydown, base business stabilizes, and multiple expands slightly to 5.5x.\"\n },\n \"bull\": {\n \"target_price\": 18.00,\n \"prob\": 0.20,\n \"notes\": \"Pipeline outperforms expectations and rapid deleveraging drives multiple expansion to 6.5x.\"\n }\n },\n \"method_notes\": \"Valuation based on 5.5x forward P/E and DCF (8.5% WACC, -1% terminal growth). Strong OCF supports deleveraging, justifying a BUY rating with ~10.5% upside despite generic headwinds. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "EquityResearch_VTRS_Base", "risks": [ "Continued base business erosion from generic price deflation.", "Failure to execute on planned divestitures at favorable valuations.", "Regulatory delays for complex generic and biosimilar pipeline assets.", "High leverage ratio limits strategic flexibility and M&A opportunities." ], "ticker": "VTRS", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady OCF allows debt paydown, base business stabilizes, and multiple expands slightly to 5.5x.", "target_price": 15 }, "bear": { "prob": 0.25, "notes": "Generic pricing worsens, deleveraging stalls, and multiple compresses to 4x forward earnings.", "target_price": 11 }, "bull": { "prob": 0.2, "notes": "Pipeline outperforms expectations and rapid deleveraging drives multiple expansion to 6.5x.", "target_price": 18 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": -0.01, "terminal_multiple": 5.5, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Debt reduction progress", "impact": "HIGH", "direction": "POS" }, { "driver": "Generic drug pricing pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Complex injectable approvals", "impact": "MED", "direction": "POS" }, { "driver": "Non-core asset divestitures", "impact": "MED", "direction": "POS" }, { "driver": "Dividend sustainability", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Interest rate environment", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on 5.5x forward P/E and DCF (8.5% WACC, -1% terminal growth). Strong OCF supports deleveraging, justifying a BUY rating with ~10.5% upside despite generic headwinds. Not investment advice.", "current_price": 13.57, "recommendation": "BUY", "thesis_bullets": [ "Extremely low forward P/E of 4.98x prices in excessive generic market pessimism.", "Strong operating cash flow of $2.3B supports aggressive debt paydown and 4% dividend.", "Divestitures of non-core assets streamline operations and accelerate deleveraging targets.", "New product pipeline in complex injectables offers modest revenue stabilization.", "High debt load and generic pricing erosion remain significant overhangs on multiple expansion." ], "target_price_6m": 14.2, "target_price_12m": 15 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 21310, "createdAt": "2026-04-09T05:22:07.525Z", "usage": { "inputTokens": 2424, "outputTokens": 874, "costUsd": 0.015336 } }, { "id": "cmnr15ijv06xtp658k98npvbp", "runId": "cmnr15ijr06xsp658mbfqgxaq", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"VTRS\",\"currency\":\"USD\",\"current_price\":13.57,\"target_price_6m\":13.98,\"target_price_12m\":14.32,\"recommendation\":\"HOLD\",\"confidence\":0.6,\"thesis_bullets\":[\"Debt reduction and dividend support the equity despite flat revenue.\",\"Core generics portfolio remains cash generative despite ongoing erosion.\",\"GAAP losses likely overstate weakness versus normalized earnings power.\",\"Pricing pressure and legacy brand declines limit top-line growth.\",\"Valuation appears near fair value, supporting a HOLD stance.\"],\"key_drivers\":[{\"driver\":\"Net debt paydown pace\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Base generics pricing\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"New product launches\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Complex injectables execution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Legacy brand erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Cost savings realization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Litigation/regulatory outcomes\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend stability\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Faster generic price erosion\",\"Launch delays or manufacturing issues\",\"Slower deleveraging or higher refinancing costs\",\"Large legal or regulatory settlements\",\"Emerging-market FX volatility\"],\"assumptions\":{\"revenue_cagr_3y\":-1.5,\"ebit_margin_target\":18,\"wacc\":9.5,\"terminal_multiple\":8},\"scenarios\":{\"bear\":{\"target_price\":10.5,\"prob\":0.3,\"notes\":\"Revenue erosion persists and debt reduction disappoints.\"},\"base\":{\"target_price\":14.3,\"prob\":0.5,\"notes\":\"Cash flow stays solid while sales decline modestly.\"},\"bull\":{\"target_price\":17.5,\"prob\":0.2,\"notes\":\"Launches, cost control, and faster deleveraging improve sentiment.\"}},\"method_notes\":\"Blended normalized cash-flow and valuation-multiple approach, anchored to snapshot quote/fundamentals. Snapshot GAAP EBITDA/FCF appear distorted by one-offs, so leverage, dividend support, and margin normalization were emphasized. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation v2", "risks": [ "Faster generic price erosion", "Launch delays or manufacturing issues", "Slower deleveraging or higher refinancing costs", "Large legal or regulatory settlements", "Emerging-market FX volatility" ], "ticker": "VTRS", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Cash flow stays solid while sales decline modestly.", "target_price": 14.3 }, "bear": { "prob": 0.3, "notes": "Revenue erosion persists and debt reduction disappoints.", "target_price": 10.5 }, "bull": { "prob": 0.2, "notes": "Launches, cost control, and faster deleveraging improve sentiment.", "target_price": 17.5 } }, "confidence": 0.6, "assumptions": { "wacc": 9.5, "revenue_cagr_3y": -1.5, "terminal_multiple": 8, "ebit_margin_target": 18 }, "key_drivers": [ { "driver": "Net debt paydown pace", "impact": "HIGH", "direction": "POS" }, { "driver": "Base generics pricing", "impact": "HIGH", "direction": "NEG" }, { "driver": "New product launches", "impact": "MED", "direction": "POS" }, { "driver": "Complex injectables execution", "impact": "MED", "direction": "POS" }, { "driver": "Legacy brand erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost savings realization", "impact": "MED", "direction": "POS" }, { "driver": "Litigation/regulatory outcomes", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend stability", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended normalized cash-flow and valuation-multiple approach, anchored to snapshot quote/fundamentals. Snapshot GAAP EBITDA/FCF appear distorted by one-offs, so leverage, dividend support, and margin normalization were emphasized. No sell-side targets used; not investment advice.", "current_price": 13.57, "recommendation": "HOLD", "thesis_bullets": [ "Debt reduction and dividend support the equity despite flat revenue.", "Core generics portfolio remains cash generative despite ongoing erosion.", "GAAP losses likely overstate weakness versus normalized earnings power.", "Pricing pressure and legacy brand declines limit top-line growth.", "Valuation appears near fair value, supporting a HOLD stance." ], "target_price_6m": 13.98, "target_price_12m": 14.32 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_051a955024e49a4d0069d75e95dee881969936d6a687c375be", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 62078, "createdAt": "2026-04-09T05:22:07.525Z", "usage": { "inputTokens": 2354, "outputTokens": 3397, "costUsd": 0.051678 } }, { "id": "cmnr15ijv06xwp6582fnf4uug", "runId": "cmnr15ijr06xsp658mbfqgxaq", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"VTRS DCF Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"VTRS\",\n \"currency\": \"USD\",\n \"current_price\": 13.57,\n \"target_price_6m\": 14.8,\n \"target_price_12m\": 16.2,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Operational efficiencies driving margin expansion despite revenue headwinds\",\n \"Biosimilar portfolio positioned for accelerated growth in key markets\",\n \"Debt reduction efforts improving financial flexibility over time\",\n \"Attractive forward P/E under 5x versus pharma peer averages\",\n \"Dividend yield offers support amid generic industry pressures\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biosimilars pipeline execution\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generics pricing pressure\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Cost restructuring program\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High debt burden\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating cash flow stability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approval success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expirations on key assets\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A and portfolio optimization\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Persistent revenue declines in legacy products\",\n \"Inability to reduce debt as planned\",\n \"Increased competition in biosimilars\",\n \"Regulatory delays on new launches\",\n \"Macro impact on drug pricing\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.09,\n \"terminal_multiple\": 11\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 10.5,\n \"prob\": 0.35,\n \"notes\": \"Revenue erosion accelerates and margins miss targets.\"\n },\n \"base\": {\n \"target_price\": 16.2,\n \"prob\": 0.45,\n \"notes\": \"Modest growth and margin expansion meet guidance.\"\n },\n \"bull\": {\n \"target_price\": 19.8,\n \"prob\": 0.2,\n \"notes\": \"Strong biosimilar uptake and faster deleveraging.\"\n }\n },\n \"method_notes\": \"DCF using 2% rev CAGR, 18% EBIT target, 9% WACC, 11x terminal. Targets imply 19% 12M upside. Consensus mentioned only in notes. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "VTRS DCF Model", "risks": [ "Persistent revenue declines in legacy products", "Inability to reduce debt as planned", "Increased competition in biosimilars", "Regulatory delays on new launches", "Macro impact on drug pricing" ], "ticker": "VTRS", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Modest growth and margin expansion meet guidance.", "target_price": 16.2 }, "bear": { "prob": 0.35, "notes": "Revenue erosion accelerates and margins miss targets.", "target_price": 10.5 }, "bull": { "prob": 0.2, "notes": "Strong biosimilar uptake and faster deleveraging.", "target_price": 19.8 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.02, "terminal_multiple": 11, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Biosimilars pipeline execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Generics pricing pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost restructuring program", "impact": "HIGH", "direction": "POS" }, { "driver": "High debt burden", "impact": "MED", "direction": "NEG" }, { "driver": "Operating cash flow stability", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approval success", "impact": "MED", "direction": "POS" }, { "driver": "Patent expirations on key assets", "impact": "MED", "direction": "NEG" }, { "driver": "M&A and portfolio optimization", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using 2% rev CAGR, 18% EBIT target, 9% WACC, 11x terminal. Targets imply 19% 12M upside. Consensus mentioned only in notes. Not investment advice.", "current_price": 13.57, "recommendation": "BUY", "thesis_bullets": [ "Operational efficiencies driving margin expansion despite revenue headwinds", "Biosimilar portfolio positioned for accelerated growth in key markets", "Debt reduction efforts improving financial flexibility over time", "Attractive forward P/E under 5x versus pharma peer averages", "Dividend yield offers support amid generic industry pressures" ], "target_price_6m": 14.8, "target_price_12m": 16.2 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "2bc72711-7059-9dde-8255-7805c58e87e0", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 14995, "createdAt": "2026-04-09T05:22:07.525Z", "usage": { "inputTokens": 2694, "outputTokens": 2421, "costUsd": 0.044397 } } ] } }